Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity

Heng Yang; Lin Xia; Jian Chen; Shuqing Zhang; Vincent Martin; Qingqing Li; Shangqing Lin; Jinfeng Chen; Joseph Calmette; Min Lü; Lingyi Fu; Jie Yang; Zhizhong Pan; Kuai Yu; Jingjing He; Eric F. Morand; Géraldine Schlecht‐Louf; Roman Krzysiek; Laurence Zitvogel; Boxi Kang; Zeming Zhang; Andrew M. Leader; Penghui Zhou; Laurence Lanfumey; Minxin Shi; Guido Guido Kroemer; Yuting Ma

doi:10.1038/s41591-019-0566-4

Related publications

Article2015

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Erika Vacchelli, Yuting Ma, Elisa Elena Baracco, Antonella Sistigu, David Enot, Federico Pietrocola, Heng Yang, Sandy Adjemian, Kariman Chaba, Michaëla Semeraro, Michele Signore, Adele De Ninno, Valeria Lucarini, Francesca Peschiaroli, Luca Businaro, Annamaria Gerardino, Gwenola Manic, Thomas Ulas, Patrick Günther, Joachim L. Schultze, Oliver Kepp, Gautier Stoll, Céline Lefèbvre, Claire Mulot, Francesca Castoldi, Sylvie Rusakiewicz, Sylvain Ladoire, Lionel Apétoh, José Manuel Bravo‐San Pedro, Monica Lucattelli, Cécile Delarasse, Valérie Boige, Michel Ducreux, Suzette Delaloge, Christophe Borg, Fabrice André, Giovanna Schiavoni, Ilio Vitale, Pierre Laurent‐Puig, Fabrizio Mattei, Laurence Zitvogel, Guido Guido Kroemer

Article2021

Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity

Discussion(0)

Related publications

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Regulation of antitumor immunity by inflammation-induced epigenetic alterations

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model

Tanespimycin as Antitumor Therapy

Combining PD-L1 blockade with immunogenic cell death induced by AIE photosensitizer to improve antitumor immunity